• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

June 3 - 7, 2022

  1. Acalabrutinib
  2. Adavosertib
  3. AZD0466
  4. AZD6738
  5. AZD8205
  6. Camizestrant
  7. Capivasertib
  8. Datopotamab deruxtecan
  9. Durvalumab
  10. Fulvestrant
  11. MEDI5752
  12. Olaparib
  13. Osimertinib
  14. Trastuzumab deruxtecan

Pdf

Acalabrutinib in Patients With Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Results of a Phase 2, Multicenter, Open-label Trial

Pdf

Acalabrutinib versus Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Results at 4 Years of Follow-up

Pdf

Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 5-Year Follow-Up of ELEVATE-TN

Html

IGNITE: A Phase II signal-seeking trial of adavosertib targeting recurrent high-grade serous ovarian cancer with Cyclin E1 over-expression with and without gene amplification

Html

Adavosertib in Combination with Carboplatin in Advanced TP53-Mutated Platinum Resistant Ovarian Cancer

Html

Pharmacokinetic and pharmacodynamic analysis of adavosertib in advanced ovarian cancer.

Pdf

Bcl-xL and association with apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer.

Html

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer

Html

First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors

Pdf

SERENA-1: Updated analyses from Parts C/D of this Phase 1 study of the next generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer

Html

Serial postoperative ctDNA monitoring of breast cancer recurrence

Html

Outcomes of recurrent and metastatic endometrial cancer (RMEC) treated with systemic progestins

Html

Circulating tumor DNA (ctDNA) and late recurrence in high-risk hormone receptor-positive, HER2-negative breast cancer (CHiRP)

Pdf

Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): Overall survival and updated progression free survival data with enhanced biomarker analysis

Pdf

Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 ≥50% and without actionable genomic alterations

Html

Impact of Consensus Molecular Subtyping (CMS) on survival in the CO.26 trial of durvalumab + tremelimumab vs best supportive care (BSC) in metastatic colorectal cancer (mCRC)

Pdf

Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON

Html

Study to evaluate intraperitoneal (IP) ONCOS-102 with systemic durvalumab in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Phase 2 results

Pdf

Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable stage III EGFR mutation-positive (EGFRm) NSCLC: a post hoc subgroup analysis from PACIFIC

Pdf

MC1923 - Phase II clinical trial of durvalumab (MEDI4736) and topotecan or lurbinectedin in patients with relapsed extensive stage small cell lung cancer previously treated with chemotherapy and immunotherapy

Html

A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)

Html

Racial disparities in the clinical use of durvalumab for patients with stage III unresectable non-small cell lung cancer treated at Veterans Health Administration facilities

Html

Durvalumab treatment initiation delays in patients with unresectable stage III non–small cell lung cancer treated at Veterans Health Administration facilities.

Html

Treatment interruptions and discontinuations among patients with stage III unresectable non–small cell lung cancer treated with durvalumab at the Veterans Health Administration.

Html

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE), an ECOG-ACRIN/NRG collaboration

Pdf

Regional subgroup analysis of the Phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC)

Pdf

Patient-reported outcomes from the Phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Html

Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors.

Pdf

Adverse events self-reported by patients (pts) with extensive-stage small-cell lung cancer (ES-SCLC) treated with durvalumab (D) + platinum-etoposide (EP) or EP in the CASPIAN study

Html

Major adverse cardiac events (MACE) with immune checkpoint inhibitor (ICI)-based therapies for cancer: A pooled analysis of investigational clinical trials sponsored by the National Cancer Institute –Cancer Therapy Evaluation Program (NCI-CTEP) in the United States and Canada

Pdf

Prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma (mUC) treated with durvalumab (D) with or without tremelimumab (T) in the DANUBE study

Pdf

DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—A phase 3 Randomized trial.

Html

CCTG BL13 A randomized phase II Trial assessing trimodality therapy with or without adjuvant durvalumab (MEDI4736) to treat patients with muscle-invasive bladder cancer (NCT03768570)

Html

Health-related quality of life in patients treated with gemcitabine/cisplatin and durvalumab ± tremelimumab in chemotherapy-naïve advanced biliary tract cancer

Html

Effect of bone metastasis on outcomes in the CCTG BR.34 phase II randomized trial of dual immune checkpoint inhibitor (ICI) treatment plus or minus chemotherapy in first-line metastatic NSCLC.

Html

The PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

Html

Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer

Html

Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results

Html

Durvalumab (D) plus tremelimumab (T) immunotherapy in patients (Pts) with advanced biliary tract carcinoma (BTC) after failure of platinum-based chemotherapy (CTx): interim results of the IMMUNOBIL GERCOR D18-1 PRODIGE-57 study

Html

Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple negative breast cancer

Html

Pathologic response after induction chemo-immunotherapy with single or double immune checkpoint inhibition in locally advanced head and neck squamous cell carcinoma (HNSCC): Expansion cohorts of the CheckRad-CD8 trial.

Html

Phase 1 clinical trial of durvalumab in children with solid and central nervous system tumors.

Html

Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1 high locally advanced non-small cell lung cancer

Html

Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): final complete resection and pathological response rates

Html

Identification of super-exhausted T cells: a novel population predictive of response to immunotherapy

Html

A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy  (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/ APGOT-OV2/ GCGS-OV3)

Html

Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC): updated results with high dimensional profiling of circulating immune cells

Html

Immune checkpoint inhibitor induced diabetes mellitus across NCI trials

Html

Serum glycoproteomic signatures and association with survival in patients with bone and soft tissue sarcoma treated with immune-checkpoint inhibitor therapy.

Html

A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results. (NCT04083365)

Html

Perioperative chemoimmunotherapy with Durvalumab for operable muscle-invasive urothelial carcinoma (MIUC): primary analysis of the single arm phase II trial SAKK 06/17

Pdf

Patient-reported outcomes for the Phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer

Html

Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).

Html

CAIRE: A basket multicenter open-label phase 2 study evaluating the EZH2 inhibitor tazemetostat in combination with durvalumab in patients with advanced solid tumors.

Html

Biomarkers for response to immunotherapy in triple-negative breast cancer – differences between survival and pCR biomarkers

Html

Trial in progress: Durvalumab and olaparib for the treatment of prostate cancer in men predicted to have a high neoantigen load.

Pdf

SAMETA: An open label, three-arm, multi-center Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC)

Html

CALYPSO: A three-arm randomised phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer

Html

A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low grade serous carcinoma

Html

Final result for SAFIA trial for neoadjuvant palbociclib in patients with operable luminal breast cancer responding to fulvestrant.

Html

Baseline and longitudinal ctDNA biomarkers in GEICAM/2013-02 (PEARL) trial cohort 2 comparing palbociclib and fulvestrant (PAL + FUL) versus capecitabine (CAPE).

Html

ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study.

Html

Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): Preliminary results from an FTIH trial.

Pdf

Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the Phase III PAOLA-1/ENGOT-ov25 trial.

Pdf

Real-world effectiveness of first-line maintenance olaparib in women with BRCA mutated advanced ovarian cancer – US retrospective cohort study

Pdf

Real-world use, tolerability and dose modifications of PARP inhibitors in ovarian cancer

Pdf

Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: overall survival (OS) results from the ORZORA study

Pdf

Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: pharmacokinetics data from the PROpel trial

Pdf

Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.

Pdf

BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer

Pdf

OReO/ENGOT Ov-38 trial: impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosis: an exploratory joint analysis of the BRCA and non-BRCA cohorts.

Pdf

Time Without Symptoms or Toxicity (TWiST) in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib or placebo plus bevacizumab: analysis of PAOLA-1/ENGOT-ov25 Phase III trial

Pdf

Quality of life in patients with advanced high-grade ovarian cancer (HGOC) receiving maintenance therapies after first-line (1L) chemotherapy in the randomized Phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644)

Html

Phase I/II investigator-initiated study of olaparib and temozolomide in SCLC: Updated analysis and CNS outcomes

Html

Results from plasmaMATCH trial treatment Cohort E: A phase II trial of olaparib and ceralasertib in patients with triple negative advanced breast cancer (CRUK/15/010)

Html

Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

Html

Genetic counselling and testing for breast and ovarian cancer in Asia: A multinational survey of unmet needs

Pdf

BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects

Html

Multicenter phase 2 trial of the PARP Inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma

Html

Preliminary results of a phase IB study of olaparib with concomitant radiotherapy in locally advanced/unresectable soft-tissue sarcoma from the French sarcoma group

Html

SCOUT-1: Prospective non-interventional study in patients with BRCA/HRD-tested ovarian cancer (OC) eligible for first-line (1L) platinum-based chemotherapy (NOGGO ov54)

Html

PARTNER: A randomized, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in patients with triple-negative and/or germline BRCA-mutated breast cancer.

Html

Safety and tolerability of olaparib combined with breast radiotherapy in patients with triple-negative breast cancer: Final results of the RADIOPARP phase 1 trial.

Html

DOLAF- An international multicenter phase II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selected using criteria that predict sensitivity to olaparib.

Pdf

A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).

Pdf

Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study

Html

Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st line treatment (PACE)

Pdf

Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study); updated results, brain efficacy and resistance mechanisms

Html

Implementation of a PREcision meDICine Thoracic (PREDICT) service using reflex testing in a large academic-community practice network

Html

Natural language processing-optimized case selection for RWE studies

Pdf

Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 Exon 19 or 20 mutations (DESTINY-Lung04)

Pdf

Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics.

Html

Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Pdf

Monitoring and management of interstitial lung disease/pneumonitis among patients with metastatic breast cancer treated with trastuzumab deruxtecan.

Pdf

Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study.

Pdf

Dose-finding and dose-expansion studies of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB07]) and HER2-low (DESTINY-Breast08 [DB08]) breast cancer (BC)

Need Help?

Contact Us

Find an MSL

Chat with a Medical Affairs Associate

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. Med Co has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice